Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (21-30 of 539) with videos related to

Pageof 54
Sort By:
Diagnostics (Basel, Switzerland)|December 16, 2017
Functional Imaging with <sup>18</sup>F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma PatientChristos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme, et al.
Leukemia & Lymphoma|April 15, 2003
Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemiaGerlinde Egerer, Hartmut Goldschmidt, Martin Zoz, et al.
Onkologie|March 1, 2013
[Therapeutic strategies in multiple myeloma: the future role of bendamustine]Hartmut Goldschmidt, Martin Kropff, Lars-Olof Mügge, et al.
Seminars in Nuclear Medicine|December 14, 2024
Radiomics and Artificial Intelligence Landscape for [<sup>18</sup>F]FDG PET/CT in Multiple MyelomaChristos Sachpekidis, Hartmut Goldschmidt, Lars Edenbrandt, et al.
Diagnostics (Basel, Switzerland)|November 10, 2019
Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRIDimitris Papamichail, Robert Hog, Hartmut Goldschmidt, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 3, 2004
[Stem cells in hematology and oncology]Hartmut Goldschmidt, Gerlinde Egerer, Stefan Fruehauf, et al.
Haematologica|February 15, 2024
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossibleMonika Engelhardt, K Martin Kortüm, Hartmut Goldschmidt, et al.
Expert Review of Hematology|June 24, 2016
Management of high-risk Myeloma: an evidence-based review of treatment strategiesNicola Lehners, Patrick J Hayden, Hartmut Goldschmidt, et al.
Annals of Hematology|February 22, 2011
Radiotherapy of solitary plasmacytomaSonja Krause, Jens Hillengass, Hartmut Goldschmidt, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 26, 2019
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment dataKatja Weisel, Heinz Ludwig, Achim Rieth, et al.
Pageof 54

Showing results (21-30 of 539) with videos related to

Sort By:
Pageof 54
Diagnostics (Basel, Switzerland)|December 16, 2017
Functional Imaging with <sup>18</sup>F-FDG PET/CT and Diffusion Weighted Imaging (DWI) in Early Response Evaluation of Combination Therapy of Elotuzumab, Lenalidomide, and Dexamethasone in a Relapsed Multiple Myeloma PatientChristos Sachpekidis, Antonia Dimitrakopoulou-Strauss, Stefan Delorme, et al.
Leukemia & Lymphoma|April 15, 2003
Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemiaGerlinde Egerer, Hartmut Goldschmidt, Martin Zoz, et al.
Onkologie|March 1, 2013
[Therapeutic strategies in multiple myeloma: the future role of bendamustine]Hartmut Goldschmidt, Martin Kropff, Lars-Olof Mügge, et al.
Seminars in Nuclear Medicine|December 14, 2024
Radiomics and Artificial Intelligence Landscape for [<sup>18</sup>F]FDG PET/CT in Multiple MyelomaChristos Sachpekidis, Hartmut Goldschmidt, Lars Edenbrandt, et al.
Diagnostics (Basel, Switzerland)|November 10, 2019
Imaging Features of Multiple Myeloma Extramedullary Lesions in the Liver with 18F-FDG PET/CT, Contrast-Enhanced CT and MRIDimitris Papamichail, Robert Hog, Hartmut Goldschmidt, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 3, 2004
[Stem cells in hematology and oncology]Hartmut Goldschmidt, Gerlinde Egerer, Stefan Fruehauf, et al.
Haematologica|February 15, 2024
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossibleMonika Engelhardt, K Martin Kortüm, Hartmut Goldschmidt, et al.
Expert Review of Hematology|June 24, 2016
Management of high-risk Myeloma: an evidence-based review of treatment strategiesNicola Lehners, Patrick J Hayden, Hartmut Goldschmidt, et al.
Annals of Hematology|February 22, 2011
Radiotherapy of solitary plasmacytomaSonja Krause, Jens Hillengass, Hartmut Goldschmidt, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 26, 2019
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment dataKatja Weisel, Heinz Ludwig, Achim Rieth, et al.
Pageof 54